“Model Context Protocol” enters protein design: “Inscilico Medicine” brings drug discovery automation to Riyadh

Inscilico Medicine places generative AI-driven protein design tools in the hands of specialists in Riyadh through an applied workshop held as part of the Riyadh Global Summit on Biomedical Technology 2026, co-organized by the Saudi Ministry of Health and the Royal Commission for Riyadh City. The workshop, led by co-founder and CEO Alex Aliber, focuses on employing the Model Context Protocol (MCP) to link foundational models with physics-simulation-based molecular models and biological databases, within the Chemistry 42 platform environment aimed at building self-automated laboratory systems.

The technical experiment relies on an integrated workflow that starts with molecular structure preparation and proceeds to physical validation, while training researchers to prioritize and evaluate drug filters by integrating specialized tools such as AlphaFold, RDKit and OpenMM.Integrating the Model Context Protocol with physics-simulation engines moves drug computing from disparate software experiments to standardized, automated production lines.This pathway enables precise understanding of kinetic binding mechanisms and free-energy calculations, thereby shortening the historical gap between theoretical three-dimensional structure prediction and complex chemical testing.

This step in the Saudi capital coincides with an expanded executive tour by the company that includes New York, Shanghai and Boston, where founder Alex Gaforonkoff discusses drug-discovery mechanisms, longevity hours and the pathways linking Eastern and Western innovation at the Morgan Stanley conference and Harvard AI-Tech lectures, alongside a dialogue pairing co-CEO Feng Ren with Nobel-prize-winning chemist Professor Michael Levitt during the Shanghai Bio Week. The expansion is underpinned by a notable financial shift, as the Hong Kong-listed company recorded revenues of roughly $106 million in the first half of 2026, with an annual growth rate of 287 percent, achieved its first profitable half-year since listing with an adjusted net profit exceeding $51 million, while declared contract values for 2026 reached about $7.3 billion, bringing the cumulative value of its major partnerships with firms such as Eli Lilly, Takeda and Servier to near $11 billion.

At the clinical level, the company announced the nomination of nine compounds for development within nine months of 2026, with its lead drug Rintusertib (ISM001-055), a generative-AI-developed treatment for idiopathic pulmonary fibrosis, entering phase III clinical trials.Moving a computationally designed molecule into phase III clinical trials and achieving semi-annual profits puts the viability of automated biotechnology before a decisive commercial and scientific proof point.This progress tests algorithms' resilience in real-world clinical settings after years of theoretical work.

In this reading we see that what changes in practice for research teams and health institutions in the Gulf and Egypt is the nature of required skills and the criteria for evaluating biomedical projects. It is no longer sufficient to run protein-structure prediction algorithms in isolation from dynamic simulation engines; instead, competencies that can link models through standardized integration protocols, enabling computational tools to communicate directly with cloud platforms and automation labs, are needed. This shift also compels regional investors and venture-capital funds to raise due-diligence standards, focusing on platforms that can demonstrate actual clinical candidate selection and secure commercial licensing deals, rather than relying on prototype models that lack a complete physical validation pathway.